Industry Portals
Medical Device Industry News
Integer a velit nec risus malesuada imperdiet id et odio. Nunc sit amet mauris dapibus, feugiat diam eget, suscipit, nam gravida nulla eget turpis commodo.
Young & Partners Forum: A Look Into the Future (October 17, 2023)
Robert Westervelt, Editor in Chief, Chemical Week Peter Young, CEO and Managing Partner, Young & Partners
Biopharma Market Review and Outlook (Pharmaceutical Executive, October 2023)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed the M&A, stock market and financing in the first half, and the outlook for 2023.
Young & Partners Forum: The Impact of AI on the Life Sciences Industry (September 18, 2023)
Panelists: Dylan Reid, Partner, Zetta Ventures Eli Weinberg, Life Sciences Partner, Bain & Company Moderator: Peter Young, CEO and Managing Partner, Young & Partners
Chem Financing to Remain Challenged (ICIS Chemical Business August 18 – August 24, 2023)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed Financings and the outlook for 2023.
Chemical M&A Activity Turns Up (ICIS Chemical Business August 11 – August 17, 2023)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed M&A and the outlook for 2023.
Young & Partners Biotech Financing Review and Outlook (June 21, 2023)
Proprietary data and analysis of the first quarter of 2023 and the current outlook.
Young & Partners Chemical M&A Review and Outlook (June 5, 2023)
Proprietary data and analysis of the first quarter of 2023 and the current outlook.
Young & Partners Pharma M&A Review and Outlook (June 2, 2023)
Proprietary data and analysis of the first quarter of 2023 and the current outlook.
Young & Partners Biotech M&A Review and Outlook (June 2, 2023)
Proprietary data and analysis of the first quarter of 2023 and the current outlook.
Biopharma M&A: Year in Review, Ripples Ahead (Pharmaceutical Executive, March 2023)
Young & Partners shares analysis of the global disruptions and uncertainties that have affected Biopharma M&A and the outlook for 2023.
Debt Financing to be difficult in 2023 (ICIS Chemical Business February 3 – February 9, 2023)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed Stock Prices and Financings and the outlook for 2023.
Young & Partners Pharma and Biotech M&A Review and Outlook (January 20, 2023)
Proprietary data and analysis of 2022 and the current outlook.
Young & Partners Chemical M&A Review and Outlook (January 17, 2023)
Proprietary data and analysis of 2022 and the current outlook.
Disruptions to hit M&A, financing (ICIS Chemical Business December 2 – December 8, 2022)
Young & Partners shows that global disruptions and uncertainties are suppressing M&A, Stock Prices and Financings.
Young & Partners 2022 Chemical Conference: Carlos Cabrera, David Roesser: Green Chemicals: Band Aid or a Real Solution?”
Carlos Cabrera, Executive Chairman, Genomatica; David Roesser, CEO, Encina
Young & Partners 2022 Chemical Conference: Jonathan Woetzel Fireside Chat: China and the U.S.: A Review of the Issues
Dr. Jonathan Woetzel, Director, McKinsey Global Institute, and Senior Partner, McKinsey & Company
Young & Partners 2022 Pharmaceutical Executive Summit: Dealing with the Disruptive Environment
Lisa Henderson, Group Editorial Director, MJH Life Sciences; Evan Loh, CEO, Paratek Pharmaceuticals; Doug Long, Vice President, IQVIA
Young & Partners 2022 Pharmaceutical Executive Summit: Doug Long: The Pharmaceutical Market: Trends, Issues and Outlook
Doug Long, Vice President, IQVIA Holdings Inc.
Young & Partners 2022 Pharmaceutical Executive Summit: Peter Marks Fireside Chat: Latest Development in Complex Biological Products
Dr. Peter Marks, Director, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration